Max-EDTA Injection

Introduction

Max-EDTA is a prescription medication that contains the active ingredient Disodium edetate. It is available in injectable form and is commonly used in the treatment of certain heavy metal poisoning, such as lead or mercury poisoning.

Uses

Max-EDTA is primarily prescribed to treat heavy metal poisoning. It works by binding to heavy metal ions in the body and facilitating their elimination through urine. This medication is often used in conjunction with other treatments, such as chelation therapy, to effectively remove toxic metals from the body.

Dosage and Administration

Max-EDTA is administered by a healthcare professional through intravenous (IV) infusion. The dosage and duration of treatment will vary depending on the severity of the poisoning and the individual patient’s condition. Follow the instructions provided by your healthcare provider and not to exceed the recommended dose.

Mechanism of Action

Disodium edetate, the active ingredient in Max-EDTA, works by forming stable complexes with heavy metal ions in the body. These complexes are then excreted through urine, aiding in the removal of toxic metals from the system. By chelating with heavy metals, Disodium edetate helps reduce their harmful effects on various organs and tissues.

Side Effects

Common side effects may include pain or discomfort at the injection site, dizziness, nausea, and vomiting. Inform your healthcare provider if these side effects persist or worsen.

Serious side effects are rare but may include allergic reactions, such as rash, itching, swelling, or difficulty breathing. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

Max-EDTA may interact with certain medications. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Some medications may interfere with the effectiveness of Max-EDTA or increase the risk of side effects. Your healthcare provider will be able to determine if any drug interactions exist and adjust your treatment plan accordingly.

Precautions

Before using Max-EDTA, inform your healthcare provider about any known allergies to Disodium edetate or any other medications. Additionally, disclose any medical conditions you have, especially kidney or liver disease, as these may affect the safety and effectiveness of the medication.

Max-EDTA is contraindicated in patients with severe renal impairment or anuria (absence of urine production). It should be used with caution in patients with mild to moderate renal impairment.

Storage

Max-EDTA should be stored at controlled room temperature, away from direct light and moisture. Keep the medication out of the reach of children and pets. Do not use the medication if the packaging is damaged or if the solution appears discolored or contains particles.

Patient Tips

• Follow the dosage and administration instructions provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for guidance on what to do.
• Inform your healthcare provider about any adverse reactions or side effects you experience during treatment.
• Attend all scheduled follow-up appointments to monitor your progress and adjust the treatment plan if necessary.
• Do not discontinue or change the dosage of Max-EDTA without consulting your healthcare provider.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Vitamins and minerals – Others (NHS UK) [Accessed 17 Jun. 2024] (online) Available at:
• Edetate disodium (edta) Side Effects: Common, Severe, Long Term (Drugs.com) [Accessed 6 Jun. 2024] (online) Available at:
• Index to Drug-Specific Information (Food and Drug Administration) [Accessed 11 Jun. 2024] (online) Available at:
• Lamas GA, Issa OM. Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients. Curr Cardiol Rep. 2016 Feb;18(2):20. doi: 10.1007/s11886-015-0690-9. [Accessed 0 Jun. 2024] Available at: